JCOGP
Journal of Controversies in Obstetrics & Gynecology and Pediatrics

As of January 2023, our "Journal of Controversies Obstetrics & Gynecology and Pediatrics" has been published under the Medihealth Academy to publish all articles, reviews and case reports on Pediatrics, especially in the field of Obstetrics and Gynecology. In order to facilitate the citation of the articles, to take our place in internationally respected indexes and to reach a wider readership, we will pay attention to the fact that our article language is only English in terms of acceptance.

eISSN: 2980-0579
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Review
Human papillomavirus vaccines in obstetrics and pediatrics: a comprehensive review
Abstract
Human papillomavirus (HPV) is a highly prevalent infection with significant implications for global public health, particularly in obstetric and pediatric populations. Persistent infection with high-risk HPV genotypes, such as HPV-16 and HPV-18, is a leading cause of cervical cancer, a major contributor to cancer-related mortality worldwide. Beyond cervical malignancies, HPV is etiologically linked to anal, vulvar, vaginal, penile, and oropharyngeal carcinomas. Additionally, it is responsible for benign but distressing conditions such as genital warts, imposing substantial psychosocial and economic burdens. Prophylactic HPV vaccines have significantly improved the prevention of HPV-associated diseases. The currently available bivalent, quadrivalent, and nonavalent vaccines target high-risk oncogenic HPV types and provide near-complete protection against vaccine-included genotypes. These vaccines function by eliciting a robust immune response, effectively neutralizing HPV before it establishes an infection. However, despite their well-documented benefits, challenges such as vaccine hesitancy, misinformation, economic barriers, and global disparities in vaccine access persist. This review provides a comprehensive analysis of HPV vaccination within obstetrics and pediatrics, emphasizing its epidemiological impact, immunological mechanisms, efficacy, safety, and implementation strategies. Furthermore, we explore existing barriers to vaccine uptake, disparities in global access, and potential future advancements, including next-generation vaccines and therapeutic interventions. Addressing these challenges through targeted public health initiatives, healthcare provider education, and equitable vaccine distribution strategies is essential to maximizing the public health impact of HPV vaccination and reducing the global burden of HPV-related diseases.

Keywords : Human papillomavirus (HPV), HPV vaccines, cervical cancer prevention, vaccine efficacy and safety, global vaccine access

Download Article


1. Malvolti S, Soble A, Bloem P, et al. The global demand and supply balance of the Human papillomavirus vaccine: implications for the global strategy for the elimination of cervical cancer.Vaccines (Basel). 2023;12(1):4. doi:10.3390/vaccines12010004
2. Serrano B, Brotons M, Bosch FX, Bruni L. Epidemiology and burden of HPV-related disease.Best Pract Res Clin Obstet Gynaecol. 2018;47:14-26. doi:10.1016/j.bpobgyn.2017.08.006
3. Bosch FX, de Sanjosé S. Chapter 1: Human papillomavirus and cervical cancer--burden and assessment of causality.J Natl Cancer Inst Monogr. 2003;(31):3-13. doi:10.1093/oxfordjournals.jncimonographs.a003479
4. Lei J, Ploner A, Elfström KM, et al. HPV vaccination and the risk of invasive cervical cancer. N Engl J Med. 2020;383(14):1340-1348. doi:10. 1056/NEJMoa1917338
5. Yan X, Li H, Song B, et al. Association of periconceptional or pregnancy exposure of HPV vaccination and adverse pregnancy outcomes: a systematic review and meta-analysis with trial sequential analysis.Front Pharmacol. 2023;14:1181919. doi:10.3389/fphar.2023.1181919
6. Niyibizi J, Zanré N, Mayrand MH, Trottier H. Association between maternal Human papillomavirus infection and adverse pregnancy outcomes: systematic review and meta-analysis.J Infect Dis. 2020; 221(12):1925-1937. doi:10.1093/infdis/jiaa054
7. Thapa HR, Unger ER, Querec TD. Evaluation of the novaplex II HPV28 detection assay for HPV typing in formalin-fixed, paraffin-embedded tissues.J Mol Diagn. 2023;25(4):211-216. doi:10.1016/j.jmoldx.2022.12.006
8. Garbuglia AR, Lapa D, Sias C, Capobianchi MR, Del Porto P. The use of both therapeutic and prophylactic vaccines in the therapy of papillomavirus disease. Front Immunol. 2020;11:188. doi:10.3389/fimmu.2020. 00188
9. Kaczmarczyk KH, Yusuf H. The impact of HPV vaccination on the prevention of oropharyngeal cancer: a scoping review.Community Dent Health. 2022;39(1):14-21 doi:10.1922/CDH_00072Kaczmarczyk08
10. Hirth J. Disparities in HPV vaccination rates and HPV prevalence in the United States: a review of the literature.Hum Vaccin Immunother. 2019;15(1):146-155. doi:10.1080/21645515.2018.1512453
11. Pomfret TC, Gagnon JM Jr, Gilchrist AT. Quadrivalent human papillomavirus (HPV) vaccine: a review of safety, efficacy, and pharmacoeconomics.J Clin Pharm Ther. 2011;36(1):1-9. doi:10.1111/j. 1365-2710.2009.01150.x
12. Genovese C, LA Fauci V, Squeri A, Trimarchi G, Squeri R. HPV vaccine and autoimmune diseases: systematic review and meta-analysis of the literature.J Prev Med Hyg. 2018;59(3):E194-E199. doi:10.15167/2421-4248/jpmh2018.59.3.998
13. Soliman M, Oredein O, Dass CR. Update on safety and efficacy of HPV vaccines: focus on gardasil.Int J Mol Cell Med. 2021;10(2):101-113. doi: 10.22088/IJMCM.BUMS.10.2.101
14. Ferrer HB, Trotter C, Hickman M, Audrey S. Barriers and facilitators to HPV vaccination of young women in high-income countries: a qualitative systematic review and evidence synthesis.BMC Public Health. 2014;14:700. doi:10.1186/1471-2458-14-700
15. Davies P, Chapman S, Leask J. Antivaccination activists on the world wide web.Arch Dis Child. 2002;87(1):22-25. doi:10.1136/adc.87.1.22
16. Leask JA, Chapman S. An attempt to swindle nature: press anti-immunisation reportage 1993-1997.Aust N Z J Public Health. 1998; 22(1):17-26. doi:10.1111/j.1467-842x.1998.tb01140.x
17. Lashuay N, Tjoa T, Zuniga de Nuncio ML, Franklin M, Elder J, Jones M. Exposure to immunization media messages among African American parents.Prev Med. 2000;31(5):522-528. doi:10.1006/pmed.2000.0745
18. Head KJ, Biederman E, Sturm LA, Zimet GD. A retrospective and prospective look at strategies to increase adolescent HPV vaccine uptake in the United States.Hum Vaccin Immunother. 2018;14(7):1626-1635. doi:10.1080/21645515.2018.1430539
19. Markowitz LE, Schiller JT. Human papillomavirus vaccines.J Infect Dis. 2021;224(12 Suppl 2):S367-S378. doi:10.1093/infdis/jiaa621
20. Branda F, Pavia G, Ciccozzi A, et al. Human papillomavirus (HPV) vaccination: progress, challenges, and future directions in global immunization strategies.Vaccines (Basel). 2024;12(11):1293. doi:10. 3390/vaccines12111293
21. Zhetpisbayeva I, Kassymbekova F, Sarmuldayeva S, Semenova Y, Glushkova N. Cervical cancer prevention in rural areas.Ann Glob Health. 2023;89(1):75. doi:10.5334/aogh.4133
22. McIndoe L, Young A, Davies C, et al. Provider preference, logistical challenges, or vaccine hesitancy? Analyzing parental decision-making in school vaccination programs: a qualitative study in Sydney, Australia.Vaccines (Basel). 2025;13(1):83. doi:10.3390/vaccines13010083
23. Binagwaho A, Wagner CM, Gatera M, Karema C, Nutt CT, Ngabo F. Achieving high coverage in Rwanda’s national human papillomavirus vaccination programme.Bull World Health Organ. 2012;90(8):623-628. doi:10.2471/BLT.11.097253
24. Shapiro GK. HPV vaccination: an underused strategy for the prevention of cancer.Curr Oncol. 2022;29(5):3780-3792. doi:10.3390/curroncol 29050303
25. Gottlieb SL, Spielman E, Abu-Raddad L, et al. WHO global research priorities for sexually transmitted infections.Lancet Glob Health. 2024; 12(9):e1544-e1551. doi:10.1016/S2214-109X(24)00266-3
26. Voss SS, Nørgaard SK, Valentiner-Branth P. Identification of subgroups in the Danish population for targeted human papillomavirus vaccination efforts.Vaccine. 2023;41(23):3525-3533. doi:10.1016/j.vaccine.2023.04.060
27. Vielot NA, Islam JY, Sanusi B, et al. Overcoming barriers to adolescent vaccination: perspectives from vaccine providers in North Carolina.Women Health. 2020;60(10):1129-1140. doi:10.1080/03630242. 2020.1802639
28. Ewongwo A, Sahor AF, Ngwa W, Nwachukwu C. A guide to global access to HPV vaccination to all women in low- and middle-income countries; a minireview of innovation and equity.Front Oncol. 2024;14: 1380663. doi:10.3389/fonc.2024.1380663
29. Shing JZ, Hu S, Herrero R, et al. Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomised Costa Rica HPV vaccine trial.Lancet Oncol. 2022;23(7):940-949. doi:10.1016/S1470-2045(22)00291-1
30. Kamolratanakul S, Pitisuttithum P. Human papillomavirus vaccine efficacy and effectiveness against cancer.Vaccines (Basel). 2021;9(12): 1413. doi:10.3390/vaccines9121413
31. Simms KT, Keane A, Nguyen DTN, et al. Benefits, harms and cost-effectiveness of cervical screening, triage and treatment strategies for women in the general population.Nat Med. 2023;29(12):3050-3058. doi: 10.1038/s41591-023-02600-4
32. Kumar S, Biswas M, Jose T. HPV vaccine: current status and future directions.Med J Armed Forces India. 2015;71(2):171-177. doi:10.1016/j.mjafi.2015.02.006
Article available in :
Volume 3, Issue 3, 2025
Page : 68-73
https://doi.org/10.51271/JCOGP-0052
Article Information
Received : 12 Şub 2025
Accepted : 19 Mar 2025
Published : 07 Tem 2025
Corresponding Author :

Tuğba Gürbüz: Department of Gynecology, Obstetric and IVF Clinic, Beylikdüzü Kolan Hospital, İstanbul, Turkiye

[email protected]
Citation : Gürbüz T, Özdil Yılmaz İÖ. Human papillomavirus vaccines in obstetrics and pediatrics: a comprehensive review. J Controv Obstetr Gynecol Ped. 2025;3(3):68-73.

Read: 234
Download : 282
Cited: 0
_Footer